In this respect, blocking of the inhibitory CTLA4 antigen on T cells with anti-CTLA4 antibodies leads to activation of T cells [44], [45] and has been proven to lead to significant survival benefits in two randomized phase III trials in patients with advanced melanoma, emphasizing the importance of immune activation in cancer [46], [47]. Here, CTLA4 is linked to melanoma.